Oncolys BioPharma Inc. [4588.T]
TOKYO, Apr 30 (Pulse News Wire) – Oncolys BioPharma Inc. (4588.T) reported positive long-term survival data for its tumor-dissolving virus OBP-301 at the International Oncolytic Virus Conference (IOVC) 2026 held in Iceland on April 29.
The presentation detailed a Phase II study combining OBP-301 with pembrolizumab in gastroesophageal adenocarcinoma patients, which began in May 2019 at Cornell University. The trial enrolled 16 patients with gastric and gastroesophageal junction cancer and evaluated the efficacy and safety of the combined treatment. Key findings included a five-year overall survival rate of 13%.
Additionally, two cases showed an increase in PD-L1 composite positivity scores post-treatment, indicating enhanced immune cell infiltration into cancer cells. In a statement, the company noted that the trial was designed for third-line gastric cancer patients and involved severely ill individuals. Based on these results, a second-line combination trial with OBP-301 and pembrolizumab is currently underway at Cornell University.
The company stated there would be no impact on its fiscal year 2026 December earnings due to this report.
🟢 Confidence: High AI-translated content.